Gouveia Andre G, Moraes Fabio Y, Lima Renato P, Viani Gustavo A
Radiation Oncology Department, Americas Centro de Oncologia Integrado, Rio de Janeiro, RJ, Brazil.
Latin America Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
Rep Pract Oncol Radiother. 2022 Sep 19;27(4):659-665. doi: 10.5603/RPOR.a2022.0070. eCollection 2022.
COVID-19 pandemic affected access to cancer treatment worldwide. However, there is a lack of data about the impact in developing countries. The objective was to evaluate COVID-19 impact on curative prostate cancer (Pca) treatment in Brazil.
With data extracted from the Brazilian Ministry of Health database, the Non-COVID and COVID periods were analyzed to compare the absolute number of radical prostatectomy (RP) and radiotherapy (RT) executed in the country and regions.
With data from 50,169 Pca patients (Non-COVID = 28,106 cases and COVID = 22,063) treated with RP or RT in Brazil, a significant decline in patients receiving RT or RP (-6.043 cases; p = 0.0001) was detected. Both treatment procedures (RT or PR) were reduced in all five Brazilian regions comparing the Non-COVID and COVID periods. Overall, there was a reduction on RP and RT procedures in 92% (24/25) and 76% (19/25) of the evaluated states, respectively. Comparing the variation of RT and RP per state between COVID and Non-COVID period, there is a significant difference (-18.6% . -29%, p = 0.03) with a higher negative impact on the RP group. The RT and RP variation had no significant relationship with the incidence of COVID cases in the states. Limitations include the non-evaluation of treatment combinations, the impact of hypofractionated radiotherapy, and other factors influencing the treatment choice.
During the COVID-19 pandemic, the curative treatment with RP and RT of Pca was abruptly limited and affected. However, the number of RP was more impacted than RT during the COVID period.
新冠疫情影响了全球癌症治疗的可及性。然而，关于其对发展中国家影响的数据却很匮乏。本研究旨在评估新冠疫情对巴西前列腺癌根治性治疗的影响。
从巴西卫生部数据库提取数据，分析非新冠时期和新冠时期，以比较该国及各地区实施的根治性前列腺切除术（RP）和放射治疗（RT）的绝对数量。
巴西50169例接受RP或RT治疗的前列腺癌患者的数据（非新冠时期 = 28106例，新冠时期 = 22063例）显示，接受RT或RP治疗的患者数量显著下降（-6043例；p = 0.0001）。与非新冠时期相比，巴西所有五个地区的两种治疗方法（RT或PR）均减少。总体而言，在评估的州中，分别有92%（24/25）和76%（19/25）的州的RP和RT手术量减少。比较新冠时期和非新冠时期各州RT和RP的变化，存在显著差异（-18.6%.-29%，p = 0.03），对RP组的负面影响更大。各州RT和RP的变化与新冠病例的发病率无显著关系。局限性包括未评估治疗组合、低分割放疗的影响以及其他影响治疗选择的因素。
在新冠疫情期间，前列腺癌的RP和RT根治性治疗突然受到限制并受到影响。然而，在新冠时期，RP的数量比RT受到的影响更大。
